Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 8/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15661647 | 0.71 | ILK (0.47) | ILKNOS1LMNAMAPTGAA | |
| SCHEMBL10002194 | 0.71 | NOS1 (0.55) | NOS1MAPT | |
| SCHEMBL1207018 | 0.70 | ALDH1A1 (0.47) | NOS1MAPTTDP1GAAKDM4E | |
| SCHEMBL15661761 | 0.69 | ILK (0.44) | ILKNOS1LMNAMAPTTDP1 | |
| SCHEMBL20040128 | 0.69 | NOS1 (0.54) | NOS1MAPTTDP1ALDH1A1HTT | |
| SCHEMBL2335843 | 0.68 | NOS1 (0.44) | NOS1 | |
| SCHEMBL15659764 | 0.67 | ILK (0.43) | ILKLMNAMAPTTDP1GAA | |
| SCHEMBL17203208 | 0.67 | NOS1 (0.46) | NOS1 | |
| SCHEMBL4614810 | 0.67 | NOS1 (0.42) | ILKNOS1MAPTTDP1GAA | |
| SCHEMBL20073715 | 0.66 | GAA (0.44) | NOS1MAPTTDP1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392389-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20150284395-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC | 2015-10-08 | — | — | US | disclosed |
| WO-2014066795-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2014-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392389-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | ILK 3392/4885NOS1 2256/4885LMNA 1114/4885 |
| US-20150284395-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | ILK 3392/4885NOS1 2256/4885LMNA 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.